Physician profile
Renee Kuneff
NPI 1518307255
$1,057.17
in general payments reported to CMS, 2019-2025
22 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.52 · 2023: $232 · 2024: $306 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,043.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $291.75 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $186.86 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $63.27 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $58.00 | 2024-2025 | |
| Abbvie INC. | $55.05 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $49.02 | 2023-2025 | Breztri, Farxiga |
| Mylan Specialty L.P. | $42.09 | 2023-2024 | Yupelri |
| Lilly USA, LLC | $34.67 | 2023-2024 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $32.60 | 2025 | Voquezna |
| Amgen INC. | $28.32 | 2024 | Repatha, Otezla |
| Ardelyx, INC. | $25.77 | 2025 | Ibsrela |
| Dynavax Technologies Corporation | $21.40 | 2025 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $20.68 | 2025 | |
| Glaxosmithkline, LLC. | $20.17 | 2023 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $19.79 | 2025 | Nexletol |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $17.12 | 2024 | Intellis Adaptivestim |
| Tolmar, INC. | $16.98 | 2025 | Jatenzo |
| Corcept Therapeutics | $16.80 | 2025 | Korlym |
| Actelion Pharmaceuticals US, INC. | $16.19 | 2024 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $13.58 | 2025 | Inspire |
| Paratek Pharmaceuticals, INC. | $13.54 | 2025 | Nuzyra |
| Otsuka America Pharmaceutical, INC. | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Kuneff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.